Disc Medicine, Inc.
IRON · XNASCIK 1816736fmd_1C8SKJ9FJZE7DHC2GMVWK51DDZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 28 | 25 | 33 | 69 | 97 | 171 |
| Selling, general and administrative | – | – | – | 22 | 33 | 65 |
| Total operating expenses | 34 | 31 | 47 | 91 | 130 | 236 |
| Operating income | (34) | (31) | (47) | (91) | (130) | (236) |
| Interest expense | 7 | 2 | – | 0 | 1 | 4 |
| Other non-operating income (expense) | – | (5) | 1 | 15 | 21 | 24 |
| Income before taxes | – | – | (47) | (76) | (109) | (212) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (47) | (76) | (109) | (212) |
| Net income | (41) | (36) | (47) | (76) | (109) | (212) |
| Net income to common shareholders | – | (36) | (47) | (76) | – | – |